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Abstract 
 
Multidrug resistance correlates with unfavourable treatment outcomes in numerous 
cancers including renal cell carcinoma. The expression and clinical relevance of 
Glutathione-S-transferase-pi (GST-pi), a multidrug resistance factor, in kidney tumors 
remain controversial. We analyzed the expression of GST-pi in 60 formalin-fixed, paraffin-
embedded renal cell carcinoma samples by immunohistochemistry and compared them 
with matched normal regions of the kidney. A significantly higher expression of GST-pi was 
observed in 87% of clear cell carcinoma and 50% of papillary subtypes. GST-pi expression 
did not correlate with tumor grade or patient survival. GST-pi is unlikely to be a prognostic 
factor for renal cell carcinoma. However, further studies with large number of samples are 
warranted to establish the role of GST-pi, if any, in intrinsic or acquired resistance of renal 
cell carcinoma to conventional treatments. Copyright: The Authors. 
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Introduction  
Despite the introduction of targeted 
therapies, metastatic renal cell carcinoma 
(RCC) continues to maintain its reputation 
as a treatment-resistant cancer. About 30% 
of the patients display intrinsic resistance 
to targeted therapy while the remaining 
70% who initially respond will eventually 
acquire resistance between 6 and 11 
months (1-4). A better understanding of 
molecules that influence drug resistance 
may shed light into the mechanisms of 
resistance of this deadly disease. In this 
regard, Glutathione-S-transferase-pi (GST-
pi), has attracted some attention in the 
past. GSTs are a family of detoxification 
enzymes that protect cells from exogenous 
and endogenous electrophiles (5). There are 
eight mammalian GST isoforms (6). RCC 
cell lines that are resistant to adriamycin 
(7) and cisplatin (8) have a higher 
expression of GST-pi when compared with 
parental cell lines. Ferric nitrilotriacetate-
induced renal tumors in rats are associated 
with a higher expression of GST-pi (9).  
However, some studies reported no 
significant correlation between GST activity 
and drug resistance (10). Baseline 
expression of GST-pi in human RCC 
samples has also been controversial. Some 
studies show that GST-pi is 
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decreased in RCC (11, 12) while others 
show no difference (13, 14). On the 
contrary, some studies report a higher 
expression of GST-pi in RCC (15-17). A 
recent evidence-based meta-analysis 
concluded no association between GST-pi 
polymorphisms and the development of 
RCC (18). In this study, we examined the 
expression of GST-pi on primary renal 
cancer specimens to assess the value of 
this protein in RCC, any possible 
association of this marker to prognosis or 
other clinicopathologic parameters, and 
finally the importance of its expression in 
tumor aggressiveness. 
Material and Methods 
Ethics approval  
Approval for this study was obtained from 
the Scientific Committee of our hospital 
(Sismanoglio General Hospital, Athens, 
Greece), Directors of the Departments, and 
the University of Athens, Greece. Informed 
consent was obtained from patients before 
the collection of the samples. 
Patient samples 
Formalin-fixed, paraffin-embedded archival 
renal tumors from 60 patients along with 
matched morphologically normal regions of 
kidneys were used in this study. The tissue 
samples were obtained from patients who 
underwent nephrectomy for kidney cancer 
at the Department of Pathology 
(Sismanoglio General Hospital, Athens, 
Greece) between 1997 and 2001. Medical 
records showed that none of the patients 
received any pre-operative therapy. Tumor 
grade was established according to the 
World Health Organization (WHO) criteria 
and the clinical staging was conducted 
according to the TNM classification 
scheme.  
Immunohistochemistry 
The expression of GST-pi was examined by 
routine immunohistochemistry technique. 
In brief, the blocks were cut into 5µm 
sections, mounted onto polylysine-coated 
slides, dewaxed in xylene, rehydrated in 
ethanol, treated with Trilogy solution (Code 
S3307; DAKO, Denmark) and heated in a 
microwave for 15 minutes. The sections 
were peroxidase-incubated for 10 minutes 
using 3% hydrogen peroxide and incubated 
for 20 minutes at room temperature with 
the GST-pi primary antibody (Thermo 
Scientific; Cat. No. RB-050-A1) at 1: 100 
dilution. Then Envision/HRP (CodeK4010; 
DAKO, Denmark) was used for 20 minutes, 
followed by diaminobenzidine (DAB) for 5 
minutes. The slides were counterstained 
with hematoxyline for 5 minutes, 
dehydrated in in ethanol, cleared in xylene 
and mounted in DePex mounting medium. 
Two pathologists independently reviewed 
the slides without the knowledge of former 
diagnosis. The intensity of GST-pi 
immunoreactivity was scored as negative 
(<10% cells with intense positive 
cytoplasmic and/or nuclear expression) or 
positive (>10% cells with intense positive 
cytoplasmic and/or nuclear expression) 
when compared with the matched 
morphologically normal regions. The distal 
tubular cells have been reported to have 
elevated concentrations of GST-pi [19]. 
Therefore we used the distal renal tubular 
cells as positive control. For negative 
controls, the primary antibody was 
omitted. 
Statistical analysis 
The statistical program SPSS for Windows, 
version 13.0 (Statistical Package for the 
Social Sciences, Chicago, IL, USA) was 
used. Correlation of staining with baseline 
characteristics was performed using chi-
square test and Fisher’s exact test. Life 
tables were estimated by Kaplan-Meier 
statistics and survival curves were 
compared using the Log-rank test. Survival 
was calculated from the day of surgery. All 
P values were two-sided and 5% was 
chosen as the level of statistical 
significance. 
 
Results 
The characteristics, tumor grade and 
immunoreactivity of all 60 sample are 
shown in the supplementary file. Of the 
60 samples, 54 were clear cell carcinomas 
and the remaining 6 were papillary 
subtypes. Eighty-seven percent (47/54) of 
clear cell and 50% (3/6) of papillary 
subtypes showed a higher expression of 
GST-pi when compared with matched 
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Figure1. GST-pi expression in renal cell carcinoma. A, Normal distal tubular cells (negative control, 
primary antibody was excluded). B, Normal distal tubular cells acting as positive control for GST-pi 
expression. C, Normal cortical region showing weak or no expression of GST-pi. D, Clear cell RCC 
showing high expression of GST-pi. E, Papillary RCC showing weak expression of GST-pi.  F, Papillary 
RCC showing high expression of GST-pi. Of the six papillary subtypes, 3 were positive and 3 were 
negative for GST-pi. 
 
normal regions. A representative 
photomicrograph for each subtype is 
shown in Figure 1. No significant 
correlation between GST-pi expression and 
tumor grade was observed (Table 1). The 
median survival of GST-pi positive patients 
was 90.37 months, whereas for negative 
patients, it was 86.04 months. Given that 
only a small number of samples were 
negative, these results are insufficient to 
reach any reasonable conclusion on the 
effect of GST-pi on survival. 
 
Discussion 
 
RCC encompasses a set of tumors 
originating from the epithelial cells of the 
renal tubules (20). The two predominant 
subtypes of RCC are clear cell (60-70%) 
and papillary (10-15%). In our series, 54 
(90%) cases were clear cell and 6 (10%) 
were papillary RCCs. GST-pi was increased 
in RCC, however, no correlation with tumor 
grade or stage was observed. Our findings 
contrast with previous studies that showed 
a decrease (11,12) or no change in GST-pi 
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       Table 1. Tumor grade and GST-pi expression 
 
 
GST-pi Expression  
Total 
Negative     Positive 
 
Tumor grade 
I-II      5 26(83.8%) 31 
III-IV      5 24(82.7%)  29 
Total     10 50  60 
 
in RCC (13, 14).   It has been suggested 
that a decrease in GST expression may 
represent a dedifferentiation program in 
RCC and that GST expression could be 
used as a prognostic marker in RCC (11). 
Our observations deviate from this 
assumption. Our findings are in agreement 
with studies that showed an increased 
expression of GST-pi in RCC. In one study 
76% of samples were positive for GST-pi 
(21), and in another study, 100% of 
samples (12/12) were positive (17). The 
five-year survival for patients with GST-pi 
positive tumors was 88% versus 50% for 
those with GST-pi negative tumors (21), a 
pattern reflected in our findings. Both 
these studies employed 
immunohistochemistry to detect GST-pi 
expression. Toffoli and colleagues (16) 
analysed mRNA expression in 38 human 
RCC samples and showed a significantly 
higher GST-pi mRNA expression in RCC. In 
conclusion, an increase in expression of 
GST-pi was observed in our study. However 
it does not appear to have a correlation 
with tumor aggressiveness. GST-pi is 
unlikely to be a prognostic factor for RCC. 
Further studies, using a large number of 
samples, are warranted to establish the 
role of GST-pi in intrinsic or acquired 
resistance of RCC.  
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